RESUMO
RESULTS: Following fighting, the adrenaline concentration was significantly higher in all athletes, most markedly in K (p < 0.001). Baseline cortisol and BDNF levels did not differ among the groups and rose significantly in all the groups after the performance. Baseline testosterone concentration was slightly higher in K than in JSW and rose in all the groups to reach similar levels; the increase in T was significantly higher than in K. CONCLUSIONS: Despite substantial differences in the characteristics of the combat sports investigated, including the type of physical effort and the required balance between restraint and aggression, the performance in each of them gives rise to similar hormonal changes with a possible exception of karate showing higher stress hormone levels.
Assuntos
Desempenho Atlético/fisiologia , Sistema Hipotálamo-Hipofisário/fisiologia , Artes Marciais/fisiologia , Sistema Hipófise-Suprarrenal/fisiologia , Sistema Nervoso Simpático/fisiologia , Luta Romana/fisiologia , Adaptação Fisiológica , Atletas/psicologia , Desempenho Atlético/psicologia , Fator Neurotrófico Derivado do Encéfalo/sangue , Epinefrina/sangue , Humanos , Hidrocortisona/sangue , Masculino , Artes Marciais/psicologia , Norepinefrina/sangue , Consumo de Oxigênio/fisiologia , Esforço Físico/fisiologia , Estresse Fisiológico , Testosterona/sangue , Luta Romana/psicologia , Adulto JovemRESUMO
Identification of a disease causing gene rarely leads to the invention of a novel therapy. Even in the case of genetic disorders or diseases greatly influenced by a hereditary component, knowledge about the genotype does not necessarily result in the invention of a novel therapy. In many cases effective treatment was introduced earlier without any existing knowledge of the molecular basis of the disease, or even without a full recognition of the pathomechanisms. Phenylketonuria is the best known example. Great expectation are connected with experimental therapy of phenylketonuria: enzymatic therapy, blocking the brain-blood barrier for phenylalanine and novel forms of low phenylalanine diet. Molecular diagnostics could be helpful in identifying patients responsive to non-standard therapy, such as tetrahydrobipterin supplementation. Novel research and development strategies will contribute to a reduction of the negative aspects of present treatment and they will facilitate normal physical a intellectual development of children with phenylketonuria, as well as to help patients in their everyday life.